Academic literature on the topic 'MERCAPTOPURINA'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'MERCAPTOPURINA.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "MERCAPTOPURINA"
Bermejo, F., A. López-Sanromán, A. Algaba, M. Van Domselaar, J. P. Gisbert, J. A. Carneros, E. Garrido, M. P. Valer, M. Rodríguez-Gandía, and B. Piqueras. "Rescate con mercaptopurina en pacientes con hepatotoxicidad por azatioprina." Gastroenterología y Hepatología 32, no. 3 (March 2009): 225. http://dx.doi.org/10.1016/j.gastrohep.2009.01.100.
Full textChávez Espinoza, Fermín, José Eguren Cáceres, Rómulo Barrionuevo Calderón, Roberto Rodríguez Luna, Américo Mayorga C., Moisés Núñez P., Luis Fernán Zegarra, and Raúl Velásquez del C. "Algunas consideraciones acerca del coriocarcinoma en el Hospital General de Arequipa." Revista Peruana de Ginecología y Obstetricia 11, no. 3 (July 9, 2015): 267–84. http://dx.doi.org/10.31403/rpgo.v11i1273.
Full textCabré, E. "Indicaciones de la azatioprina (o 6-mercaptopurina) en la enfermedad inflamatoria intestinal." Gastroenterología y Hepatología 25, no. 5 (January 2002): 319–26. http://dx.doi.org/10.1016/s0210-5705(02)79028-6.
Full textMartín-Ezquerra, Gemma, Jesús Molinero-Caturla, and P. a. u. Umbert-Millet. "Quistes miliares en placa en las extremidades. Posible toxicodermia por 6-mercaptopurina." Actas Dermo-Sifiliográficas 95, no. 7 (January 2004): 449–50. http://dx.doi.org/10.1016/s0001-7310(04)76856-8.
Full textMartí, Nuria, and Esperanza Jordá. "Erupción acneiforme tras retirada de 6-mercaptopurina y metotrexato en una niña con leucemia." Piel 26, no. 8 (October 2011): 424–25. http://dx.doi.org/10.1016/j.piel.2011.03.013.
Full textPayeras Capó, M. A., A. Escarda Gelabert, A. Erimeiku Barahona, I. Pérez Medrano, E. Antón Valentí, and D. Ginard Vicens. "Hiperplasia nodular regenerativa: hepatotoxicidad por 6-mercaptopurina en un paciente con enfermedad de Crohn." Enfermedad Inflamatoria Intestinal al Día 16, no. 2 (May 2017): 84–86. http://dx.doi.org/10.1016/j.eii.2016.12.008.
Full textBastida Paz, Guillermo, Pilar Nos Mateu, Mariam Aguas Peris, Belén Beltrán Niclós, María Rodríguez Soler, and Julio Ponce García. "Optimización del tratamiento inmunomodulador con azatioprina o 6-mercaptopurina en pacientes con enfermedad inflamatoria intestinal." Gastroenterología y Hepatología 30, no. 9 (October 2007): 511–17. http://dx.doi.org/10.1157/13111681.
Full textGisbert, J. P., P. M. Linares, A. G. McNicholl, J. Maté, and F. Gomollón. "EFICACIA DE LA AZATIOPRINA Y LA MERCAPTOPURINA EN LA COLITIS ULCEROSA. REVISIÓN SISTEMÁTICA Y METAANÁLISIS." Gastroenterología y Hepatología 32, no. 3 (March 2009): 213–14. http://dx.doi.org/10.1016/j.gastrohep.2009.01.075.
Full textFranco, Gabriele Alvernaz Silva, Liliane Faria da Silva, Flavio Luiz Seixas, Fernanda Garcia Bezerra Góes, and Emília Gallindo Cursino. "Orientações para o cuidado domiciliar de crianças e adolescentes em quimioterapia antineoplásica oral." Research, Society and Development 10, no. 4 (April 16, 2021): e40310414530. http://dx.doi.org/10.33448/rsd-v10i4.14530.
Full textASSUMPÇÃO, Izaura Ramos, Maraci RODRIGUES, and Dorina BARBIERI. "Tratamento da retocolite ulcerativa inespecífica em criança com enemas contendo butirato: relato de caso." Arquivos de Gastroenterologia 36, no. 4 (December 1999): 238–43. http://dx.doi.org/10.1590/s0004-28031999000400012.
Full textDissertations / Theses on the topic "MERCAPTOPURINA"
Corrales, Roberta Cristina Novaes Reis. "Síntese e avaliação biológica de derivados de 6-mercaptopurina, carboidratos e aminoálcoois." Universidade Federal de Juiz de Fora (UFJF), 2011. https://repositorio.ufjf.br/jspui/handle/ufjf/4290.
Full textApproved for entry into archive by Adriana Oliveira (adriana.oliveira@ufjf.edu.br) on 2017-05-13T12:05:49Z (GMT) No. of bitstreams: 1 robertacristinanovaesreiscorrales.pdf: 3333393 bytes, checksum: a90614981046f5f6e0791845afd8c1fd (MD5)
Made available in DSpace on 2017-05-13T12:05:49Z (GMT). No. of bitstreams: 1 robertacristinanovaesreiscorrales.pdf: 3333393 bytes, checksum: a90614981046f5f6e0791845afd8c1fd (MD5) Previous issue date: 2011-06-17
CAPES - Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
A tese de doutorado intitulada Síntese e Avaliação Biológica de Derivados de 6-Mercaptopurina, Carboidratos e Aminoálcoois está apresentada em três capítulos que descrevem a síntese e caracterização de compostos com potencial atividade antiparasitária (Leishmania, Plasmodium berghei), antibacteriana (bactérias Gram positiva e negativa, Mycobacterium tuberculosis) e em macrófagos peritoneais de mamíferos. Foram obtidos 53 compostos neste trabalho, sendo 30 inéditos, a saber: no capitulo 1 foi descrita a síntese de 27 compostos, sendo 14 derivados inéditos de 6mercaptopurina (6-MP); no capítulo 2 foi descrita a síntese de 14 compostos, sendo 6 derivados inéditos da D-glicose e 1 derivado inédito da D-ribonolactona; no capítulo 3 foi descrita a síntese de 14 compostos, sendo 9 aminoálcoois inéditos. O primeiro capítulo mostra a síntese de derivados de 6-MP contendo 1,2,3-triazol e derivados de esteróides. Os derivados triazólicos de 6-MP foram obtidos através de uma reação de cicloadição 1,3-dipolar tipo “click” usando um alcino terminal e um grupo azido. Os derivados de 6-MP contendo esteróides, sem o espaçador triazólico, foram obtidos através de uma reação de substituição nucleofílica entre o sal de 6-MP e mesilatos do ácido cólico e do ácido desoxicólico. Dentre os compostos submetidos à avaliação biológica, os derivados de 6-MP conjugados com esteróides apresentaram melhor atividade em Leishmania e a maioria apresentou importante atividade em P. berghei. Nenhum composto testado apresentou citotoxicidade in vitro para macrófagos peritoneais de camundongos até a máxima concentração de 48 µg/mL. O segundo capítulo mostra a síntese e caracterização de derivados da D-glicose contendo 1,2,3-triazol, obtidos através de reação tipo “click” e de derivados da D-gliconolactona e D-ribonolactona. Apesar dos compostos testados não terem apresentado atividade antiparasitária e antibacteriana efetiva, nenhum apresentou toxidez para os macrófagos de mamíferos. O terceiro capítulo descreve a síntese e caracterização de derivados aminoálcoois aromáticos com variada extensão de cadeia e de função química e apresentaram importante atividade biológica, principalmente em L. major. As estruturas dos produtos obtidos foram elucidadas pelos seus espectros na região do infravermelho, Ressonância Magnética Nuclear de 1H e 13C, Mapa de contornos homonuclear COSY, faixa de fusão e espectros de massas de alta resolução.
The doctoral thesis entitled Synthesis and Biological Evaluation of Derivatives of 6-Mercaptopurine, Carbohydrates and Aminoalcohol is presented in three chapters that describe the synthesis and characterization of compounds with potential antiparasitic activity (Leishmania, Plasmodium berghei), antibacterial (bacteria Gram positive and negative, Mycobacterium tuberculosis) and peritoneal macrophages of mammals. 53 compounds were obtained in this work, with 30 firsts, namely: Chapter 1 was described in the synthesis of compounds 27, 14 novel derivatives of 6-mercaptopurine (6MP), was described in Chapter 2 the synthesis of compounds 14, 6 being derived from unpublished 1 D-glucose and derived novel D-ribonolactona, was described in Chapter 3 the synthesis of compounds 14, 9 amino unpublished. The first chapter shows the synthesis of derivatives of 6-MP containing 1,2,3triazole derivatives and steroids. The triazole derivatives of 6-MP were obtained by a reaction of type 1,3-dipolar cycloaddition "click" using a terminal alkyne and an azide group. Derivatives of 6-MP containing steroids, without the spacer triazole, was obtained through a nucleophilic substitution reaction between the salt of 6-MP and mesylates cholic acid and deoxycholic acid. Among the compounds subjected to biological evaluation, derivatives of 6-MP in conjunction with steroids showed better activity in Leishmania and most showed a significant activity in P. berghei. No compound tested showed cytotoxicity in vitro for mouse peritoneal macrophages to g / mL.µthe maximum concentration of 48 µg/mL. The second chapter shows the synthesis and characterization of D-glucose derivatives containing 1,2,3-triazole, obtained by reaction type "click" derivatives of Dgliconolactona and D-ribonolactona. Although the compounds tested did not show effective antibacterial and antiparasitic activity, showed no toxicity to mammalian macrophages. The third chapter describes the synthesis and characterization of aromatic amino derivatives with varied chain length and chemical function and had significant biological activity, especially in L. Major. The structures of the products obtained were elucidated by their spectra in the infrared, 1H NMR and 13C, homonuclear COSY contour map, melting point and mass spectra with high resolution.
LIMA, Carlos Henrique Vasconcelos de. "Farmacogenética do Gene TPMT na resposta A 6-Mercaptopurina, em pacientes com Leucemia Linfoblástica Aguda." Universidade Federal do Pará, 2016. http://repositorio.ufpa.br/jspui/handle/2011/7252.
Full textApproved for entry into archive by Edisangela Bastos (edisangela@ufpa.br) on 2017-01-09T17:41:43Z (GMT) No. of bitstreams: 2 license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) Dissertacao_FarmacogeneticaGeneTPMT.pdf: 1407662 bytes, checksum: 32630679859b6a050376eb589c280057 (MD5)
Made available in DSpace on 2017-01-09T17:41:43Z (GMT). No. of bitstreams: 2 license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) Dissertacao_FarmacogeneticaGeneTPMT.pdf: 1407662 bytes, checksum: 32630679859b6a050376eb589c280057 (MD5) Previous issue date: 2016-03-03
Leucemia Linfoblástica Aguda (LLA) é o tipo de câncer mais frequente em crianças menores de 15 anos de idade. O 6-mercaptopurina (6-MP) é um dos agentes quimioterápicos mais amplamente utilizado no tratamento da LLA infantil. Polimorfismos no gene Tiopurina s-metiltransferase (TPMT) podem estar associados a variações individuais na resposta ao tratamento da LLA infantil, como aumento de toxicidade grave (grau 3 e 4). O objetivo deste trabalho foi associar polimorfismos do gene TPMT: TPMT*2 (238G>C), TPMT*3A (460G>A e 719A>G), TPMT*3B (460G>A), TPMT*3C (719A>G), TPMT*8 (644G>A) e a variante intrônica rs12201199 (94T>A) com a ocorrência de toxicidades graves em pacientes com LLA tratados com 6-MP, na Região Norte do Brasil. Foram investigados 137 pacientes infantis com LLA tratados no Hospital Ophir Loyola, no estado do Pará. O polimorfismo rs12201199 foi genotipado pela técnica de PCR em tempo Real (equipamento 7500 Real-Time PCR System) e os demais polimorfismos foram genotipados por sequenciamento direto, utilizando o sequenciador automático ABI PRISM 3130 Genetic Analyzer (Applied Biosytems, CA, USA). Os haplótipos entre os polimorfismos investigados foram derivados através de estimativas de máxima verossimilhança utilizando o programa PHASE. Foi empregado um painel de 48 Marcadores Informativos de Ancestralidade, como controle genômico na amostra e as análises estatísticas foram realizadas no programa SPSS v.20.0 (SPSS, Chicago, IL, EUA). Todos os testes estatísticos consideraram a probabilidade (p-valor) significativa quando ≤0,05. Em relação à ascendência genômica, observou-se que a composição étnica dos pacientes com LLA foi de 44% Europeu, 22% Africano e 34% Ameríndio. Entre as toxicidades relatadas, a infecciosa foi a mais prevalente (86%), seguida da hematológica (65%), da gastrointestinal (64,8%) e toxicidade no sistema nervoso central (29,9%). A frequência alélica do polimorfismo rs12201199 foi de 0,482 entre os indivíduos estudados. As variantes haplotípicas mais prevalentes foram TPMT*3A (7,6%), seguido pelo TPMT*3C e TPMT*8, ambos com 7,3%. Não foi observada uma associação significativa entre o perfil de metabolização deficiente da TPMT com nenhuma das toxicidades graves relatadas nos pacientes com LLA estudados. No entanto, os dados encontrados mostram que há uma significativa relação entre o polimorfismo do gene TPMT (rs12201199) e a ocorrência de toxicidade infecciosa grave durante o tratamento da LLA infantil. Foi observado que os pacientes que possuem o genótipo homozigoto mutante AA para o polimorfismo no gene TPMT têm um risco de 4,098 vezes maior de apresentar toxicidade grave infecciosa durante o tratamento para LLA infantil em relação aos que apresentam os outros genótipos. Este resultado pode ser importante para ajudar a predizer riscos de toxicidade durante o tratamento, contribuindo para um melhor prognóstico individual dos pacientes com LLA infantil.
Acute Lymphoblastic Leukemia (ALL) is the most common type of cancer in children under 15 years of age. 6-mercaptopurine (6-MP) is one of the most widely used chemotherapeutic agents in the treatment of childhood ALL. Polymorphisms in thiopurine S-methyltransferase gene (TPMT) may be associated with individual variation in the response to treatment of childhood ALL, such as increased severe toxicity (grade 3 and 4). The aim of this study was to associate polymorphisms of TPMT gene: TPMT*2 (238G>C), TPMT*3A (460G>A and 719A>G), TPMT*3B (460G>A), TPMT*3C (719A>G), TPMT* 8 (644G>A) and intronic variant rs12201199 (94T>A) with the occurrence of serious toxicities in patients with ALL treated with 6-MP, in Northern Brazil. One hundred thirty-seven pediatric patients with ALL and treated at the Ophir Loyola Hospital in the state of Pará were investigated. The rs12201199 polymorphism was genotyped by real-time PCR (equipment 7500 Real-Time PCR System) and other polymorphisms were genotyped by direct sequencing using the automated sequencer ABI PRISM 3130 Genetic Analyzer (Applied Biosytems, CA, USA). The haplotypes among the studied polymorphisms were derived via maximum likelihood estimates using the program PHASE. A panel of 48 markers Ancestry Informative was used as genomic control in the sample and statistical analyses were performed using SPSS v.20.0 software (SPSS, Chicago, IL, USA). All statistical tests considered the probability (p) significant when ≤0, 05. In relation to the genomic ancestry, it was noted that the ethnic composition of ALL patients was 44% Caucasian, 22% African and 34% Amerindian. Among the reported toxicities, infectious was most prevalent (86%), followed by hematological (65%), gastrointestinal (64.8%) and central nervous system toxicity (29.9%). Allele frequency of polymorphism rs12201199 was 0.482 among the studied subjects. The most prevalent haplotype variants were TPMT*3A (7.6%), followed by TPMT*3C and TPMT*8, both 7.3%. There was no significant association between poor metabolism profiles of TPMT with none of the serious toxicities reported in the studied patients with LLA. However, our data show that there is a significant relationship between the polymorphism of TPMT gene (rs12201199) and the occurrence of severe infectious toxicity during treatment of childhood ALL. It has been observed that patients who have mutant homozygous AA genotype for this polymorphism in TPMT gene have 4.098 times higher risk of presenting severe infectious toxicity during the treatment for childhood ALL compared to those with the other genotypes. This result may be important to help predict risk of toxicity during treatment, contributing to a better individual prognosis of patients with childhood ALL.
Canales, López Cristina. "Asociación de efectos adversos al tratamiento de mercaptopurinas con polimorfismos genéticos de la enzima TPTM en niños con leucemia linfoblástica aguda tratados en el Hospital Dr. Luis Calvo Mackenna." Tesis, Universidad de Chile, 2012. http://www.repositorio.uchile.cl/handle/2250/111229.
Full textLa Leucemia Linfoblástica Aguda (LLA) es la neoplasia más común en niños, siendo la 6-mercaptopurina (6-MP) una droga que cumple un rol fundamental para el tratamiento de esta neoplasia. Sin embargo, se han asociado al uso de esta droga una serie de efectos adversos. La presencia de polimorfismos presentes en genes que codifican enzimas involucradas en su metabolización, aparece como una de las principales causantes de los efectos adversos a 6-MP. Uno de los polimorfismos involucrados en el metabolismo de la 6-MP, corresponde a aquellos presentes en el gen TPMT*1 que codifica la enzima Tiopuril S-metiltransferasa (TPMT). Se han asociado a diversos polimorfismos en este gen, la presencia de concentraciones plasmáticas tóxicas de nucleótidos de tioguanina (TGNs), un metabolito de la 6-MP, aumentando el riesgo de desarrollar eventos adversos durante la terapia, lo que conduce al abandono o suspensión de la terapia, obligando a controlar o reducir las dosis recibidas de 6-MP en pacientes que presentan algún polimorfismo en el gen TPMT*1. El conocimiento de la prevalencia de este polimorfismo y su efecto en el tratamiento de la LLA ha permitido el desarrollo de una farmacogenética efectiva, mejorando sustancialmente la calidad de vida de los pacientes durante el tratamiento. Estudios previos de nuestro grupo permitieron encontrar la presencia de polimorfismos en el gen TPMT en un 8% de una población de 103 niños chilenos con LLA. En este trabajo se analizó la relación existente entre la presencia de polimorfismo en el gen TPMT*1 con los efectos adversos y la disminución de la dosis de 6-MP durante el periodo de mantención en el tratamiento de la LLA. El análisis de 35 pacientes con LLA atendidos en el Hospital Dr. Luis Calvo Mackenna muestra que se administra una dosis significativamente menor de 6-MP durante el periodo de mantención en los niños con LLA que presentan un alelo polimórfico del gen TPMT*1. Los resultados obtenidos apoyan el uso de una farmacogenética efectiva para el tratamiento de la LLA en nuestro país.
Acute lymphoblastic leukemia (ALL) is the most common malignancy in children. The drug 6-mercaptopurine (6-MP) plays a fundamental role in the treatment of this malignancy. However, a number of side effects have been associated with the use of this drug. The presence of polymorphisms in genes encoding enzymes involved in its metabolism, appears as a major cause of adverse effects of 6-MP. Several of the polymorphisms involved in the metabolism of 6-MP corresponds to those present in the gene encoding the TPMT*1 enzyme, Tiopuril S-methyltransferase (TPMT). Some of these have been associated with the presence of toxic plasma concentrations of thioguanine nucleotides (TGNs), metabolites of 6-MP. These metabolites increase the risk of adverse events during therapy, leading to the abandonment or suspension of therapy, and demand an increased control of 6-MP doses in patients with a polymorphism of this gene. Knowledge of the prevalence of this polymorphism and its effect on the treatment of ALL has allowed the development of an effective pharmacogenetic approach, substantially improving the quality of life of patients during treatment. Previous studies from our group found polymorphisms in the TPMT gene in 8% of a population of 103 Chilean children with ALL. In this work we analyzed the relationship between the presence of one polymorphism of the TPMT*1gene with the side effects and the decrease of the 6-MP dose during the treatment of ALL and the decrease of the 6-MP dose during maintenance treatment of ALL. The analysis of 35 patients with ALL treated at the Hospital Dr. Luis Calvo Mackenna shows that there is a significant decrease in the dose of 6-MP during maintenance in children with ALL with a polymorphic allele of the TPMT*1gene. The results support the use of an effective pharmacogenetics strategy for the treatment of ALL in our country.
Souza, Nicolli Bellotti de. "Avaliação da atividade antiplasmodial de análogos da cloroquina." Universidade Federal de Juiz de Fora (UFJF), 2011. https://repositorio.ufjf.br/jspui/handle/ufjf/2495.
Full textApproved for entry into archive by Diamantino Mayra (mayra.diamantino@ufjf.edu.br) on 2016-09-26T20:18:43Z (GMT) No. of bitstreams: 1 nicollibellottidesouza.pdf: 1508500 bytes, checksum: 7150363e1a046cd4741555cb142f6f21 (MD5)
Made available in DSpace on 2016-09-26T20:18:43Z (GMT). No. of bitstreams: 1 nicollibellottidesouza.pdf: 1508500 bytes, checksum: 7150363e1a046cd4741555cb142f6f21 (MD5) Previous issue date: 2011-02-22
CAPES - Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
A malária é causada por protozoários do gênero Plasmodium e é responsável por 250 milhões de casos e 1 milhão de mortes anualmente. Um dos principais empecilhos para o controle da doença é o desenvolvimento de resistência do parasito aos fármacos comumente usados, o que torna urgente a pesquisa por novos antimaláricos. Nesse contexto, análogos de cloroquina acoplados a 6-mercaptopurina e a alquil aminas e complexos de platina foram avaliados quanto a atividade antimalárica utilizando o teste supressivo descrito por Peters em modelo murino de infecção por Plasmodium berghei NK65. Tais análogos exibiram altos valores de supressão da parasitemia, entre 60% e 94% em comparação com o controle não tradado. Considerando o papel imunossupressor de derivados de purina, o análogo de cloroquina acoplado a 6-mercaptopurina MPQUI foi avaliado quanto a aspectos imunológicos (contagem de leucócitos específicos, dosagem de TNF-α e IL-10), não interferindo na resposta imune tendo como base os parâmetros analisados. Portanto, esses análogos devem ser objetos de futuras pesquisas, podendo fornecer novos antimaláricos, já que apresentaram-se promissores e não influenciaram a resposta imune nos parâmetros analisados.
Malaria is caused by protozoan parasites of the genus Plasmodium and is responsible for 250 million cases and 1 million deaths annually. One of the main obstacles for the disease control is the development of resistance by the parasite to the commonly used antimalarials, what makes the research for new ones urgent. In this context, chloroquine analogs attached to 6-mercaptopurine and to alkyl-amines and platinum complexes were evaluated for their antimalarial activity using the 4-day suppressive test described by Peters which was carried out in mice infected with Plasmodium berghei NK65. These analogs exhibited high values of parasitemia suppression, which ranged from 60% to 94% in comparison to untreated control. Considering the immune suppressor role of purine derivates, the chloroquine analog attached to 6-mercaptopurine MPQUI was evaluated for immunological aspects (specific leukocytes count, TNF-α and IL-10 measurements in sera of mice), revealing no interference in the immune response considering these parameters. Therefore, these analogs may be objects of further research, aiming at new antimalarials, since they were shown to be promising and did not influence the immune response in the parameters analyzed.
Vashist, Usha. "Aspectos biológicos da inoculação experimental e atividade malaricida da 4-(6-mercaptopurina)-7-cloroquinolina em Gallus gallus Linnaeus, 1758 experimentalmente infectados por Plasmodium (Novyella) juxtanucleare Versiani & Gomes, 1941 (Apicomplexa, Plasmodiidae)." Universidade Federal de Juiz de Fora (UFJF), 2007. https://repositorio.ufjf.br/jspui/handle/ufjf/2915.
Full textApproved for entry into archive by Adriana Oliveira (adriana.oliveira@ufjf.edu.br) on 2016-10-25T12:31:34Z (GMT) No. of bitstreams: 1 ushavashist.pdf: 630186 bytes, checksum: 745a558bec12dae7850947a507e2f344 (MD5)
Made available in DSpace on 2016-10-25T12:31:34Z (GMT). No. of bitstreams: 1 ushavashist.pdf: 630186 bytes, checksum: 745a558bec12dae7850947a507e2f344 (MD5) Previous issue date: 2007-02-23
Plasmodium juxtanucleare é o agente causador da malária aviária que ocorre em alguns estados do Brasil. Esta malária está relacionada a diversos sinais clínicos e pode causar danos em criações rústicas de aves. O modelo aviário já foi utilizado para a investigação de drogas no combate à malária e hoje em dia o modelo mais utilizado é o Plasmodium berghei em roedores. A busca por anti-maláricos e malaricidas é de extrema relevância. O objetivo deste trabalho foi verificar o efeito da 4-(6-MERCAPTOPURINA)-7-CLOROQUINOLINA, uma substância recém sintetizada a partir da cloroquina, sobre a malária aviária em Gallus gallus e aprimorar o modelo aviário para testes de potenciais malaricidas. Para o encontro de uma ave doadora, foram visitadas no município de Juiz de Fora duas granjas e feitos esfregaços sangüíneos de 30 aves. A prevalência foi de 100%. Dentre as 30 aves examinadas, as seis com os maiores valores de parasitemia foram adquiridas e levadas para o laboratório. Para verificar qual o melhor dia para a retirada de sangue de aves infectadas e imunossuprimidas pelo acetato de metilprednisolona, cinco das seis aves receberam em dose única este imunossupressor e uma serviu como controle. A parasitemia das aves foi acompanhada por 26 dias após o dia da imunossupressão, por meio de esfregaços sangüíneos preparados a cada dois dias. Também foram aferidos o peso e temperatura corporal e feitos microhematócritos sangüíneos. Verificou-se que ao 10º dia pós-imunossupressão ocorreu pico de parasitemia. Houve queda de peso corporal e correlação com a parasitemia. Ocorreu pouca variação na temperatura corporal e hematócrito e não houve correlação destes com a parasitemia. Em outras oito aves adquiridas em casa comercial com 15 dias de idade, foram realizadas infecções experimentais com sangue inoculado via intramuscular e via intraperitonial nas doses de 0,3mL e 0,5mL para as duas vias. Durante um mês as aves tiveram o valor médio de parasitos acompanhado para comparar qual a via mais efetiva e se havia diferença entre as doses testadas no estabelecimento da infecção. Não foi observada diferença entre as xv dosagens, mas foi possível verificar que a infecção via intraperitonial atinge mais rapidamente o pico de parasitemia, com médias de parasitos mais altas, entretanto ao fim do experimento o número total de parasitos quase não diferiu entre as doses e vias. Para testar o efeito malaricida da 4-(6-MERCAPTOPURINA)-7-CLOROQUINOLINA, uma droga derivada da cloroquina, recém sintetizada, foram infectados 45 pintos, Leghorn branco, via intramuscular. As aves foram separadas em quatro grupos experimentais com 15 aves por grupo (Grupo1- não infectado, Grupo 2- infectado e sem tratamento, Grupo 3- infectado e tratado com a cloroquina e grupo 4- infectado e tratado com o derivado da cloroquina). A droga foi administrada via gavagem por 4 dias consecutivos na dose de 100mg/Kg de peso vivo. Para a avaliação do efeito malaricida da droga, as aves tiveram o número médio de parasitos encontrados acompanhados por esfregaços sangüíneos feitos a cada dois dias após o décimo dia da inoculação. Também foram aferidos o peso e temperatura corporal a cada dois dias e hematócrito a cada quatro dias. O derivado da cloroquina teve atividade malaricida, mantendo a parasitemia mais baixa em relação ao grupo controle não tratado e ao grupo controle tratado com a cloroquina. Entretanto em todos os grupos a parasitemia se manteve baixa. Sugere-se a investigação da ação malaricida desta droga em modelos com P. berghei ou culturas com P. falciparum.
Plasmodium juxtanucleare is the agent of the avian malaria that occurs in some states of Brazil. This malaria is related to several clinical signs and it can cause damages in the poultry section. The aviary model was already used for the investigation of drugs in the combat to the malaria and nowadays the model more used is the Plasmodium berghei in rodents. The search for anti-malarial drugs is of extreme importance. The aim of this study was to accomplish experimental infections of Plasmodium juxtanucleare in Gallus gallus and to test a substance recently synthesized, the 4-(9H-purin-6-ylthio)-7-cloroquinoline, derived of the cloroquine, to verify their effects on the avian malaria and to improve the aviary model for these types of tests. For a bird donor's encounter, two chicken farms were visited in the Juiz de Fora city and blood smears made in 30 hens. The prevalence was 100%. Among the 30 examined hens, six with the largest parasitemia values had been acquired and taken to the laboratory. To verify which the best day to retreat the blood to infected hens, five of the six hens received only dose of the imunossupressor substance (metilprednisolon acetate) and one served as control. The parasitaemia of the hens was accompanied by 26 days after the day of the imunossupression, through blood smears prepared each two days. The weight and corporal temperature were checked and made blood hematocrits. It was verified that to the 10th day powder-imunossupression it happened parasitaemia pick. There were fall of body weight and correlation with the parasitaemia. There was a little variation in the body temperature and hematocrite and there was not correlation of these with the parasitaemia. In other eight acquired hens in commercial house with 15 days old, experimental infections were accomplished with blood inoculated through intramuscle and intraperitoneally in the 0,3mL and 0,5mL for the two routes. During one month the hens had the value of parasites accompanied to compare which the most effective route and difference among the doses tested in the establishment of the infection. Significant difference was not observed among the xvii doses but it was possible to verify that the infection through intraperitonial reaches the parasitemia pick more quickly, with higher averages of parasites, however to the end of the experiment the total number of parasites differed hardly between the doses and routes. To test the effect a derived drug of the cloroquine, 45 chicks were infected, white Leghorn, through intramuscle route . The hens were separate in four experimental groups, 15 chicks for group (Group1 - no infected, Group 2 - infected and without treatment, Group 3 - infected and treated with the cloroquine and Group 4 - infected and treated with derived of the cloroquine) The drug was administered four consecutive days in the 100mg/Kg of alive weight dose. For the evaluation of the antimalarial effect of the drug, the hens had the number of parasites accompanied by blood smears done each two days after the tenth day of the inoculation. Also the weight and corporal temperature were checked each two days and hematocrit four days. Derived of the cloroquine had antimalarial activity, reducing the number of parasites and maintaining the lowest parasitaemia in relation to the group not treated and to the group treated with cloroquine.
Londero, Margherita. "Sviluppo di strategie farmacologiche per la personalizzazione della terapia della leucemia linfoblastica acuta nel bambino." Doctoral thesis, Università degli studi di Trieste, 2015. http://hdl.handle.net/10077/10852.
Full textL'attività dell'enzima tiopurina-S-metil transferasi (TPMT) è un determinante importante di eventi avversi severi durante il trattamento della leucemia linfoblastica acuta (LLA) con l'antimetabolita mercaptopurina. Recentemente è stato dimostrato che la proteina PACSIN2 modula l'attività di TPMT e la tossicità indotta da mercaptopurina, mediante un meccanismo molecolare che si ipotizza riguardi la regolazione dell'autofagia. Nell’ambito del protocollo italiano per il trattamento della LLA AIEOP 2009, si vogliono sviluppare strategie farmacologiche (farmacogenetiche, farmacocinetiche e farmacodinamiche) in vitro da integrare agli attuali parametri di risposta del paziente per personalizzare la terapia. Queste strategie comprendono la valutazione dell’attività e di polimorfismi genetici di enzimi importanti per la biotrasformazione della mercaptopurina, ovvero TPMT ed inosina trifosfato-pirofosfatasi (ITPA), della concentrazione dei metaboliti attivi della mercaptopurina e della sensibilità in vitro dei blasti dei pazienti raccolti alla diagnosi e trattati con diversi farmaci antitumorali. Si vuole poi validare l’effetto dei polimorfismi di PACSIN2 sull’attività dell’enzima TPMT. I dati preliminari ottenuti sostengono il ruolo dei polimorfismi d’interesse sulla farmacocinetica della mercaptopurina. In particolare, la casistica considerata finora valida un contributo dello SNP di PACSIN2 rs2413739 sull’attività enzimatica di TPMT. Lo studio è in continuo aggiornamento. Il suo ampliamento e l’integrazione dei dati farmacologici con i dati clinici dei pazienti contribuiranno a comprendere l’impatto di queste variabili farmacocinetiche/farmacogenomiche sull’efficacia e la tossicità del trattamento con tiopurine. Per determinare se PACSIN2 e l'autofagia contribuiscono alla variabilità interindividuale nell'attività di TPMT e nella suscettibilità alla tossicità da mercaptopurina abbiamo eseguito degli esperimenti in cellule con meccanismo di autofagia alterato (ovvero fibroblasti murini embrionali, MEF, da topi con ATG7 disattivato) e alterazione di PACSIN2 (cellule NALM6 con silenziamento di PACSIN2). Le cellule con meccanismo di autofagia alterato esprimono costitutivamente livelli più alti di PACSIN2 endogeno; questo avviene anche per altre proteine correlate all'autofagia come p62. Il trattamento con rapamicina induce la degradazione di PACSIN2 nelle cellule con autofagia funzionante, ma non in quelle con meccanismo di autofagia alterato. Il silenziamento dell'espressione di PACSIN2 ha indotto un aumento nel livello basale di autofagia, come documentato dall'accumulo di LC3-II e autofagosomi. La sequenza proteica di PACSIN2 contiene due siti di legame per LC3 e la co-immunoprecipitazione di PACSIN2 e LC3 dimostra l'interazione delle due proteine nelle linee cellulari NALM6. La stabilità di TPMT è diminuita quando l'espressione di PACSIN2 è alterata, in confronto a cellule con livelli normali di PACSIN2. Qui dimostriamo che PACSIN2 è bona fide una proteina dell'autofagia e che il suo ruolo come modulatore dell'autofagia influenza la variabilità interindividuale nell'attività di TPMT.
XXVI Ciclo
1980
Monteil-Ganiere, Catherine. "Mercaptopurine et polymorphisme génétique." Nantes, 2003. https://archive.bu.univ-nantes.fr/pollux/show/show?id=6d743aea-4878-4f8f-a5a1-0dbe73f78509.
Full textTPMT genotype and activity were determined in 304 adult blood donors, 147 children and 18 newborns (cord bloods), all Caucasian. TPMT activity ranged from 0. 43 to 30. 38 U/mL PRBC in adults, from 8. 25 to 30. 0 U/mL PRBC in children and from 9. 24 to 22. 79 U/mL PRBC in cord bloods. There was no significant difference between cord bloods and adults (p = 0. 424). But we found a slightly lower TPMT activity in children than in adults (p = 0. 016). In the children and cord bloods group, no significant correlation was evidenced between TPMT and age (p = 0. 127): TPMT is already mature at birth. In the whole population, 91. 9% was homozygous wild-type, 7. 9% heterozygous and 0. 2% homozygous and 0. 2% homozygous mutant. The frequency of mutant allele was 3. 0% for TPMT/*3A, 0. 7% for TPMT*2 and 0. 4% for TPMT*3C. For TPMT activities close to the antimode value, there was an overlap between homozygous and heterozygous subjects concerning 4. 5% of subjects. Consequences of TPMT polymorphism were studied in 54 leukemic children treated with 6-MP during maintenance phase. 39 (90. 7%) TPMT genotypes were homozygous *1/*1 and 4 (9. 3%) heterozygous *1/*3A. Diagnosis TPMT activity is 20. 4% lower than in the reference children population. During maintenance, TPMT activity was 27. 4% higher than the reference population. Our results showed an inverse correlation between TPMT activity and red blood cells TGNs, which are 6-MP active metabolites, responsible, at least in part, for the anti-leukemic effect. TPMT enzyme plays a major role for 6-MP metabolisation and treatment success
Monteil-Ganiere, Catherine Bourin Michel Pineau Alain. "Mercaptopurine et polymorphisme génétique." [S.l.] : [s.n.], 2003. http://theses.univ-nantes.fr/thesemed/DOCmonteil.pdf.
Full textRabello, Celia Maria de Almeida. "An investigation of the effects of variation in drug metabolism in children with acute lymphoblastic leukaemia undergoing continuing therapy." Thesis, University of Newcastle Upon Tyne, 1996. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.308017.
Full textTAI, ROYA. "Devenir au long cours des patients atteints de maladie de crohn mis en remission complete par l'azathioprine ou la 6-mercaptopurine." Reims, 1993. http://www.theses.fr/1993REIMM076.
Full textBooks on the topic "MERCAPTOPURINA"
Bianchi, C. P. Skeletal Muscle Toxicity of 6-Mercaptopurine, 14 (Skeletal Muscle Toxicity of 6-Mercaptopurine, 14). Princeton Scientific Publishing, 1986.
Find full textBook chapters on the topic "MERCAPTOPURINA"
Urlep, Darja, and Erasmo Miele. "Mercaptopurine Therapy." In Pediatric Inflammatory Bowel Disease, 391–99. Cham: Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-14744-9_29.
Full textCuffari, Carmen. "6-Mercaptopurine Therapy." In Pediatric Inflammatory Bowel Disease, 375–81. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-49215-5_30.
Full textCuffari, Carmen. "6-Mercaptopurine Therapy." In Pediatric Inflammatory Bowel Disease, 331–37. New York, NY: Springer New York, 2012. http://dx.doi.org/10.1007/978-1-4614-5061-0_31.
Full textFriedman, Antony B., Miles P. Sparrow, and Peter R. Gibson. "Thiopurines: Azathioprine, Mercaptopurine, and Thioguanine." In Compendium of Inflammatory Diseases, 1255–65. Basel: Springer Basel, 2016. http://dx.doi.org/10.1007/978-3-7643-8550-7_186.
Full textFriedman, Antony B., Miles P. Sparrow, and Peter R. Gibson. "Thiopurines; Azathioprine, Mercaptopurine and Thioguanine." In Encyclopedia of Inflammatory Diseases, 1–12. Basel: Springer Basel, 2016. http://dx.doi.org/10.1007/978-3-0348-0620-6_186-1.
Full textHelbig, W., R. Krahl, M. Kubel, F. Fiedler, U. Schattmann, and R. Rohrberg. "Preliminary Results of a Multicenter Study of Chronic Myelogenous Leukemia Comparing Busulfan/6-Mercaptopurine with Dibromomannitol/6-Mercaptopurine." In Leukemias, 309–12. Berlin, Heidelberg: Springer Berlin Heidelberg, 1993. http://dx.doi.org/10.1007/978-3-642-77083-8_54.
Full textStet, E. H., R. A. De Abreu, Y. P. G. Janssen, J. P. M. Bökkerink, and J. M. F. Trijbels. "6-Mercaptopurine Metabolism in Two Leukemic Cell Lines." In Advances in Experimental Medicine and Biology, 83–86. Boston, MA: Springer US, 1991. http://dx.doi.org/10.1007/978-1-4899-2638-8_18.
Full textKaplan, Gil, and Lloyd R. Sutherland. "Conventional Medical Management of Crohn’s Disease: Azathioprine and 6-Mercaptopurine." In Crohn's Disease and Ulcerative Colitis, 379–85. Boston, MA: Springer US, 2011. http://dx.doi.org/10.1007/978-1-4614-0998-4_29.
Full textZimm, Solomon, and David G. Poplack. "New methods of administering old drugs: IV infusion of mercaptopurine." In The Role of Pharmacology in Pediatric Oncology, 115–23. Dordrecht: Springer Netherlands, 1987. http://dx.doi.org/10.1007/978-94-009-4267-7_7.
Full textChaparro, María, and Javier P. Gisbert. "Antimetabolite Therapy in Ulcerative Colitis: Azathioprine, 6-Mercaptopurine, and Methotrexate." In Medical Therapy of Ulcerative Colitis, 135–43. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-1677-1_11.
Full textConference papers on the topic "MERCAPTOPURINA"
Tasdemir, Halil Ugur, and Ercan Türkkan. "Theoretical EPR study of 6-Mercaptopurine." In TURKISH PHYSICAL SOCIETY 32ND INTERNATIONAL PHYSICS CONGRESS (TPS32). Author(s), 2017. http://dx.doi.org/10.1063/1.4976363.
Full textKumar, Subodh, Ann O'Callaghan, and Anoop J. Chauhan. "Pulmonary Lymphomatoid Granulomatosis Associated With Mercaptopurine." In American Thoracic Society 2012 International Conference, May 18-23, 2012 • San Francisco, California. American Thoracic Society, 2012. http://dx.doi.org/10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a6643.
Full textRashidpour, Neda, Vikas Kashid, and Vaishali Shah. "Effect of tautomerism on Au-6-mercaptopurine nanocluster stability." In SOLID STATE PHYSICS: PROCEEDINGS OF THE 57TH DAE SOLID STATE PHYSICS SYMPOSIUM 2012. AIP, 2013. http://dx.doi.org/10.1063/1.4791075.
Full textSun, Xiao-Qing, Kondababu Kurakula, Chris Happé, Denielli da Silva Goncalves Bos, Ingrid Schalij, Anton Vonk-Noordegraaf, Frances S. de Man, Harm-Jan Bogaard, and Marie-Jose Goumans. "The effect of 6-mercaptopurine treatment on experimentally induced pulmonary arterial hypertension." In ERS International Congress 2017 abstracts. European Respiratory Society, 2017. http://dx.doi.org/10.1183/1393003.congress-2017.oa4660.
Full textBotros, L., R. Szulcek, S. Jansen, J. Smits, P. Phelp, K. Kurakula, M. J. Goumans, et al. "Anti-Proliferative Therapy with 6-Mercaptopurine Improves Hemodynamics and BMPR2 Expression in Pulmonary Arterial Hypertension." In American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a2495.
Full textCunningham, Bethany, Jayasree Krishnamurthy, Jennifer Deutsch, Lab Assistant, Michael Flora, and Kenneth Lieuw. "Elucidating the Mechanism of 6-mercaptopurine Induced Hepatotoxicity and How Combination with Allopurinol Eliminates the Hepatotoxicity*." In Selection of Abstracts From NCE 2016. American Academy of Pediatrics, 2018. http://dx.doi.org/10.1542/peds.141.1_meetingabstract.744.
Full textLopez-Montero, E., A. Mosquera-Torre, M. Touris-Lores, B. Sanchez-Iglesias, B. Bernardez-Ferran, and MJ Lamas-Diaz. "PS-086 Adding low dose allopurinol as hepatoprotector to the maintenance treatment with mercaptopurine in children with acute lymphoblastic leukaemia." In 22nd EAHP Congress 22–24 March 2017 Cannes, France. British Medical Journal Publishing Group, 2017. http://dx.doi.org/10.1136/ejhpharm-2017-000640.592.
Full textSingh, Balraj, Vanessa N. Sarli, and Anthony Lucci. "Abstract 2003: Evaluation of 6-mercaptopurine in a cell culture model of adaptable triple-negative breast cancer with metastatic potential." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-2003.
Full textSingh, Balraj, Vanessa N. Sarli, and Anthony Lucci. "Abstract 2003: Evaluation of 6-mercaptopurine in a cell culture model of adaptable triple-negative breast cancer with metastatic potential." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-2003.
Full textPatchva, Dorababu, Vijay Gandhi Linga, and Raghunadharao Digumarti. "Abstract 1874: The role of functional polymorphisms in folate metabolism on 6-mercaptopurine-mediated hematological toxicity in children with acute lymphoblastic leukemia." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-1874.
Full textReports on the topic "MERCAPTOPURINA"
Lee, Yeonhong, Eun Jeong Jang, Ha-Young Yoon, Jeong Yee, and Hye-Sun Gwak. Effect of ITPA polymorphism on adverse drug reactions of 6-mercaptopurine in pediatric patients with acute lymphoblastic leukemia: a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, February 2022. http://dx.doi.org/10.37766/inplasy2022.2.0110.
Full text